Amdocs Financials

AOS Stock

EUR 60.30 2.04 3.27%

Financial data analysis helps to double-check if markets are presently mispricing Amdocs Limited. We were able to interpolate thirty-five available fundamental indicators for Amdocs Limited, which can be compared to its peers. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Amdocs to be traded at €57.89 in 90 days.

Covid

Interest Hikes

Amdocs Balance Sheet Chart

At this time, Amdocs' Cash is most likely to decrease significantly in the upcoming years. The Amdocs' current Net Receivables is estimated to increase to about 617 M, while Other Current Liabilities is projected to decrease to roughly 147.9 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Key indicators impacting Amdocs' financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Operating Income

665.8 M

934 M

Way Down

Slightly volatile

Understanding current and past Amdocs Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amdocs' financial statements are interrelated, with each one affecting the others. For example, an increase in Amdocs' assets may result in an increase in income on the income statement.

Amdocs Stock Summary

Amdocs competes with Beazer Homes, JSC Halyk, American Homes, Laurentian Bank, and BOVIS HOMES. Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company was founded in 1988 and is headquartered in Chesterfield, Missouri. AMDOCS LTD operates under Software - Infrastructure classification in Germany and is traded on Frankfurt Stock Exchange. It employs 25000 people.

Foreign Associate	USA
Specialization	Information Technology, Software - Infrastructure
Instrument	Germany Stock View All
Exchange	Frankfurt Exchange
ISIN	GB0022569080
Business Address	625 Maryville Centre
Sector	Software
Industry	Information Technology
Benchmark	Dow Jones Industrial
Website	www.amdocs.com
Phone	314 212 7000
Currency	EUR - Euro

You should never invest in Amdocs without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Amdocs Stock, because this is throwing your money away. Analyzing the key information contained in Amdocs' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Amdocs Key Financial Ratios

There are many critical financial ratios that Amdocs' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Amdocs Limited reports annually and quarterly.

	Revenue	4.53 B
	Gross Profit	1.72 B
	EBITDA	1.02 B
	Net Income	564.7 M
	Total Asset	6.25 B

More Fundamentals

Amdocs Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	6.4B	6.4B	6.4B	6.2B	7.2B	6.4B
Other Current Liab	658.1M	203.6M	189.2M	173.0M	155.7M	147.9M
Retained Earnings	6.2B	6.5B	6.8B	7.2B	8.2B	5.8B
Accounts Payable	134.4M	293.3M	305.9M	371.2M	426.8M	448.2M
Cash	573.4M	520.1M	346.1M	325.0M	292.5M	527.0M
Long Term Debt	645.1M	645.7M	646.3M	646.9M	743.9M	608.6M
Net Receivables	789.6M	733.0M	665.7M	589.8M	530.8M	617.0M
Good Will	2.7B	2.7B	2.8B	2.9B	3.3B	2.7B
Other Current Assets	12.0M	224.6M	228.5M	331.4M	381.1M	400.1M
Total Liab	2.8B	2.9B	2.9B	2.8B	3.2B	2.5B
Total Current Assets	2.0B	1.9B	1.8B	1.6B	1.4B	1.6B
Intangible Assets	178.3M	181.5M	160.7M	156.3M	140.7M	173.0M
Net Invested Capital	4.2B	4.2B	4.1B	4.1B	4.7B	4.4B
Net Working Capital	750.5M	558.3M	300.3M	233.3M	210.0M	199.5M
Capital Stock	4.5M	4.6M	4.6M	4.6M	5.3M	5.0M

Amdocs Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	26.4M	23.1M	34.9M	42.4M	48.8M	51.2M
Total Revenue	4.6B	4.9B	5.0B	4.5B	5.2B	4.6B
Gross Profit	1.6B	1.7B	1.8B	1.7B	2.0B	1.6B
Operating Income	664.8M	724.9M	759.7M	812.2M	934.0M	665.8M
Research Development	354.7M	374.9M	360.8M	340.8M	392.0M	330.1M
Cost Of Revenue	3.0B	3.2B	3.2B	2.8B	3.2B	3.0B
Income Before Tax	648.4M	636.4M	591.1M	693.2M	797.2M	637.7M
Net Income	549.5M	540.7M	493.2M	564.7M	649.4M	539.2M
Tax Provision	98.9M	93.4M	94.8M	125.5M	144.3M	102.4M
Net Interest Income	(26.4M)	(1.8M)	(17.4M)	(33.3M)	(30.0M)	(28.5M)
Interest Income	7.8M	21.2M	17.5M	9.2M	10.5M	10.2M

Amdocs Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Amdocs Limited. It measures of how well Amdocs is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Amdocs brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Amdocs had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Amdocs has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (capital allocation) and investing in non-business activities like paying off debt or making acquisitions.

	2021	2022	2023	2024	2025	2026 (projected)
Investments	(12.3M)	(224.5M)	(127.4M)	170.0M	195.5M	205.3M
Change In Cash	(135.7M)	(53.3M)	(174.0M)	(21.1M)	(19.0M)	(19.9M)
Depreciation	224.5M	195.7M	193.1M	195.4M	224.8M	219.7M
Dividends Paid	186.1M	199.5M	212.0M	(224.4M)	(202.0M)	(191.9M)
Capital Expenditures	227.7M	124.4M	105.5M	104.0M	119.5M	169.0M
Net Income	549.5M	540.7M	496.3M	564.7M	649.4M	539.5M
End Period Cash Flow	573.4M	520.1M	346.1M	325.0M	292.5M	461.2M
Free Cash Flow	529.5M	698.3M	618.9M	645.1M	741.9M	613.2M
Other Non Cash Items	564K	579K	596K	608K	699.2K	557.2K

Amdocs Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Amdocs's current stock value. Our valuation model uses many indicators to compare Amdocs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amdocs competition to find correlations between indicators driving Amdocs's intrinsic value. More Info.

Amdocs Limited is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Amdocs Limited is roughly 2.02 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amdocs' earnings, one of the primary drivers of an investment's value.

Amdocs Limited Total Assets Over Time

Most indicators from Amdocs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amdocs Limited current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amdocs Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Amdocs Stock please use our How to Invest in Amdocs guide.The current Selling General Administrative is estimated to decrease to about 542.7 M. The current Tax Provision is estimated to decrease to about 102.4 M

	2023	2024	2025	2026 (projected)
Gross Profit	1.8B	1.7B	2.0B	1.6B
Total Revenue	5.0B	4.5B	5.2B	4.6B

Gross Profit Total Revenue

Amdocs fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Deferred Long Term Liab	Non Current Assets Total	Non Currrent Assets Other
Total Assets		-0.62	0.69	0.73	0.88	-0.74	0.92	0.64	-0.61	0.92	0.59	-0.53	0.92	-0.58	0.44	-0.62	0.98	-0.67	-0.66	-0.66	-0.22	0.83	0.96	-0.7	0.98	0.93
Other Current Liab	-0.62		-0.71	-0.53	-0.56	0.54	-0.73	-0.87	0.7	-0.6	-0.44	0.45	-0.74	0.59	-0.65	0.62	-0.59	0.46	0.75	0.73	0.4	-0.68	-0.68	0.65	-0.69	-0.71
Total Current Liabilities	0.69	-0.71		0.57	0.65	-0.51	0.72	0.77	-0.63	0.58	0.56	-0.55	0.74	-0.43	0.63	-0.65	0.67	-0.29	-0.65	-0.57	-0.21	0.77	0.69	-0.49	0.71	0.74
Total Stockholder Equity	0.73	-0.53	0.57		0.47	-0.55	0.63	0.62	-0.47	0.62	0.5	-0.34	0.7	-0.58	0.43	-0.27	0.58	-0.49	-0.64	-0.88	-0.18	0.92	0.65	-0.65	0.68	0.61
Other Liab	0.88	-0.56	0.65	0.47		-0.52	0.89	0.65	-0.6	0.87	0.36	-0.53	0.82	-0.37	0.54	-0.78	0.91	-0.55	-0.54	-0.44	-0.52	0.71	0.87	-0.46	0.9	0.93
Net Tangible Assets	-0.74	0.54	-0.51	-0.55	-0.52		-0.81	-0.49	0.82	-0.74	-0.85	-0.05	-0.87	0.79	-0.05	0.47	-0.71	0.88	0.85	0.63	-0.13	-0.64	-0.72	0.91	-0.79	-0.65
Retained Earnings	0.92	-0.73	0.72	0.63	0.89	-0.81		0.73	-0.84	0.94	0.69	-0.37	0.98	-0.66	0.45	-0.72	0.91	-0.79	-0.83	-0.64	-0.34	0.83	0.9	-0.78	0.97	0.95
Accounts Payable	0.64	-0.87	0.77	0.62	0.65	-0.49	0.73		-0.69	0.56	0.35	-0.47	0.74	-0.65	0.85	-0.77	0.59	-0.39	-0.78	-0.77	-0.57	0.8	0.73	-0.52	0.73	0.74
Cash	-0.61	0.7	-0.63	-0.47	-0.6	0.82	-0.84	-0.69		-0.74	-0.76	-0.06	-0.86	0.65	-0.27	0.64	-0.58	0.82	0.94	0.64	0.29	-0.68	-0.64	0.86	-0.72	-0.73
Other Assets	0.92	-0.6	0.58	0.62	0.87	-0.74	0.94	0.56	-0.74		0.63	-0.35	0.91	-0.48	0.29	-0.56	0.92	-0.81	-0.69	-0.6	-0.28	0.74	0.88	-0.78	0.93	0.94
Long Term Debt	0.59	-0.44	0.56	0.5	0.36	-0.85	0.69	0.35	-0.76	0.63		0.07	0.75	-0.54	-0.04	-0.3	0.55	-0.75	-0.74	-0.49	0.23	0.55	0.54	-0.85	0.59	0.55
Net Receivables	-0.53	0.45	-0.55	-0.34	-0.53	-0.05	-0.37	-0.47	-0.06	-0.35	0.07		-0.31	0.07	-0.7	0.35	-0.56	-0.18	0.02	0.25	0.28	-0.42	-0.53	-0.04	-0.47	-0.51
Good Will	0.92	-0.74	0.74	0.7	0.82	-0.87	0.98	0.74	-0.86	0.91	0.75	-0.31		-0.74	0.41	-0.66	0.88	-0.82	-0.89	-0.72	-0.24	0.86	0.88	-0.85	0.96	0.91
Short Term Investments	-0.58	0.59	-0.43	-0.58	-0.37	0.79	-0.66	-0.65	0.65	-0.48	-0.54	0.07	-0.74		-0.35	0.41	-0.5	0.65	0.84	0.67	0.07	-0.66	-0.58	0.67	-0.68	-0.5
Other Current Assets	0.44	-0.65	0.63	0.43	0.54	-0.05	0.45	0.85	-0.27	0.29	-0.04	-0.7	0.41	-0.35		-0.65	0.41	0.04	-0.37	-0.47	-0.67	0.59	0.53	-0.05	0.49	0.55
Other Stockholder Equity	-0.62	0.62	-0.65	-0.27	-0.78	0.47	-0.72	-0.77	0.64	-0.56	-0.3	0.35	-0.66	0.41	-0.65		-0.66	0.37	0.58	0.43	0.58	-0.57	-0.73	0.37	-0.7	-0.7
Total Liab	0.98	-0.59	0.67	0.58	0.91	-0.71	0.91	0.59	-0.58	0.92	0.55	-0.56	0.88	-0.5	0.41	-0.66		-0.65	-0.59	-0.53	-0.21	0.73	0.95	-0.63	0.96	0.93
Short Long Term Debt	-0.67	0.46	-0.29	-0.49	-0.55	0.88	-0.79	-0.39	0.82	-0.81	-0.75	-0.18	-0.82	0.65	0.04	0.37	-0.65		0.78	0.52	0.08	-0.56	-0.62	0.88	-0.73	-0.68
Total Current Assets	-0.66	0.75	-0.65	-0.64	-0.54	0.85	-0.83	-0.78	0.94	-0.69	-0.74	0.02	-0.89	0.84	-0.37	0.58	-0.59	0.78		0.79	0.23	-0.79	-0.68	0.88	-0.76	-0.7
Short Term Debt	-0.66	0.73	-0.57	-0.88	-0.44	0.63	-0.64	-0.77	0.64	-0.6	-0.49	0.25	-0.72	0.67	-0.47	0.43	-0.53	0.52	0.79		0.25	-0.85	-0.7	0.77	-0.67	-0.61
Intangible Assets	-0.22	0.4	-0.21	-0.18	-0.52	-0.13	-0.34	-0.57	0.29	-0.28	0.23	0.28	-0.24	0.07	-0.67	0.58	-0.21	0.08	0.23	0.25		-0.35	-0.31	-0.02	-0.3	-0.44
Common Stock	0.83	-0.68	0.77	0.92	0.71	-0.64	0.83	0.8	-0.68	0.74	0.55	-0.42	0.86	-0.66	0.59	-0.57	0.73	-0.56	-0.79	-0.85	-0.35		0.78	-0.68	0.84	0.79
Property Plant Equipment	0.96	-0.68	0.69	0.65	0.87	-0.72	0.9	0.73	-0.64	0.88	0.54	-0.53	0.88	-0.58	0.53	-0.73	0.95	-0.62	-0.68	-0.7	-0.31	0.78		-0.67	0.95	0.92
Deferred Long Term Liab	-0.7	0.65	-0.49	-0.65	-0.46	0.91	-0.78	-0.52	0.86	-0.78	-0.85	-0.04	-0.85	0.67	-0.05	0.37	-0.63	0.88	0.88	0.77	-0.02	-0.68	-0.67		-0.72	-0.67
Non Current Assets Total	0.98	-0.69	0.71	0.68	0.9	-0.79	0.97	0.73	-0.72	0.93	0.59	-0.47	0.96	-0.68	0.49	-0.7	0.96	-0.73	-0.76	-0.67	-0.3	0.84	0.95	-0.72		0.95
Non Currrent Assets Other	0.93	-0.71	0.74	0.61	0.93	-0.65	0.95	0.74	-0.73	0.94	0.55	-0.51	0.91	-0.5	0.55	-0.7	0.93	-0.68	-0.7	-0.61	-0.44	0.79	0.92	-0.67	0.95

Click cells to compare fundamentals

Amdocs Account Relationship Matchups

Amdocs fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	6.4B	6.4B	6.4B	6.2B	7.2B	6.4B
Other Current Liab	658.1M	203.6M	189.2M	173.0M	155.7M	147.9M
Retained Earnings	6.2B	6.5B	6.8B	7.2B	8.2B	5.8B
Accounts Payable	134.4M	293.3M	305.9M	371.2M	426.8M	448.2M
Cash	573.4M	520.1M	346.1M	325.0M	292.5M	527.0M
Long Term Debt	645.1M	645.7M	646.3M	646.9M	743.9M	608.6M
Net Receivables	789.6M	733.0M	665.7M	589.8M	530.8M	617.0M
Good Will	2.7B	2.7B	2.8B	2.9B	3.3B	2.7B
Other Current Assets	12.0M	224.6M	228.5M	331.4M	381.1M	400.1M
Total Liab	2.8B	2.9B	2.9B	2.8B	3.2B	2.5B
Total Current Assets	2.0B	1.9B	1.8B	1.6B	1.4B	1.6B
Intangible Assets	178.3M	181.5M	160.7M	156.3M	140.7M	173.0M
Net Invested Capital	4.2B	4.2B	4.1B	4.1B	4.7B	4.4B
Net Working Capital	750.5M	558.3M	300.3M	233.3M	210.0M	199.5M
Capital Stock	4.5M	4.6M	4.6M	4.6M	5.3M	5.0M

Amdocs February 6, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Amdocs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amdocs Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amdocs Limited based on widely used predictive technical indicators. In general, we focus on analyzing Amdocs Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amdocs's daily price indicators and compare them against related drivers.

	Information Ratio	(0.17)
	Maximum Drawdown	9.11
	Value At Risk	(2.18)
	Potential Upside	2.09

Complementary Tools for Amdocs Stock analysis

When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.

	Commodity Directory Find actively traded commodities issued by global exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC